Description
Listing and trading permission for 16,61,000 equity shares issued on preferential basis pursuant to conversion of warrants, effective January 1, 2026.
Summary
BSE has listed and permitted trading of 16,61,000 new equity shares of NOVELIX PHARMACEUTICALS LIMITED (Scrip Code: 536565) effective January 1, 2026. These shares were issued at a premium of Rs. 10/- to Promoter and Non-Promoter on preferential basis pursuant to conversion of warrants. The shares rank pari-passu with existing equity shares.
Key Points
- 16,61,000 equity shares of Rs. 10/- each issued at premium of Rs. 10/-
- Issued to Promoter and Non-Promoter on preferential basis
- Securities issued pursuant to conversion of warrants
- Date of allotment: October 23, 2025
- Issue price: Rs. 20/- per share
- Distinctive numbers: 14480001 to 16141000
- ISIN: INE314I01036
- Shares rank pari-passu with old equity shares
Regulatory Changes
No regulatory changes introduced.
Compliance Requirements
Trading members must note the listing and trading permission for these new securities effective January 1, 2026.
Important Dates
- Allotment Date: October 23, 2025
- Trading Commencement: January 1, 2026
- Lock-in Expiry (11,25,000 shares): July 31, 2027
- Lock-in Expiry (5,36,000 shares): July 31, 2026
Lock-in Details
- 11,25,000 shares (Dist. Nos. 14480001-15605000): Locked-in until July 31, 2027
- 5,36,000 shares (Dist. Nos. 15605001-16141000): Locked-in until July 31, 2026
Impact Assessment
Limited impact confined to NOVELIX PHARMACEUTICALS LIMITED shareholders and traders. The preferential allotment increases total equity base by 16,61,000 shares. Lock-in provisions on all new shares restrict immediate supply, with differential lock-in periods (1.5 years for 5,36,000 shares and 2.5 years for 11,25,000 shares) that will gradually release shares into the market.
Impact Justification
Routine listing of preferential allotment shares from warrant conversion for a single company with limited market-wide impact